Recognition of Severe Eosinophilic Asthma & Comorbidities
Science & Innovation Webinar
Webinar Recorded on July 21, 2021
Sponsored by GSK
Approximately 50% of severe asthma patients have eosinophilic inflammation. Elevated eosinophil counts (blood and sputum) are associated with several clinical features including severe airflow limitation, decreased symptom control and increased risk for exacerbations and hospitalizations, as well as other outcomes. Therefore, Severe Eosinophilic Asthma (SEA) burden to patients includes decreased lung function and physical activity, missed days of work and school, and increased mortality.
This program will review SEA:
- Definitions and guideline recommendations for management
- The role of eosinophils in SEA and outcomes, including exacerbations, and
- Comorbidities, with a focus on Chronic rhinosinusitis with nasal polyps.
At the end of the program, attendees should be able to:
- Understand the burden of Severe Eosinophilic Asthma (SEA)
- Discuss the guidelines for appropriate SEA treatments
- Discuss the role of eosinophils and their link to patient outcomes, and
- Recognize the comorbidities associated with SEA.
- Tom Corbridge, MD, FCCP
Emeritus Physician, Northwestern Memorial Hospital
Adjunct Professor of Medicine, Division of Pulmonary and Critical Care Medicine, Northwestern University Feinberg School of Medicine
Senior Director, Medical Respiratory, GSK
- Jared Silver, MD, PhD
Indication Lead, GSK
This webinar is sponsored, developed and presented by the sponsor. The content of this Science & Innovation Theater Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.